GlaxoSmithKline (GSK) has been given initial orders from the US Department of Health and Human Services for an A (H1N1) influenza vaccine antigen and the company’s proprietary adjuvant system, AS03, to shore up its pandemic influenza preparations.

The vaccine antigen will be made from the newly isolated A (H1N1) influenza strain, while the adjuvant system can be added to the antigen at the time of administration.

GSK is presently working with the US Food and Drug Administration and other government authorities in connection with its adjuvant and A (H1N1) candidate vaccine development.

GSK expects to fill the US adjuvant order within the next few months, with the first doses of the vaccine antigen expected to be available four to six months after the company gets the H1N1 seed strain, subject to regulatory approval.